Essential Bio
Essential Bio
Develops advanced biological tools and reagents for research and diagnostics.
About
What does Essential Bio do?
Essential Bio is a biotechnology company focused on creating innovative biological tools and reagents. Their products aim to accelerate research in areas such as genomics, proteomics, and drug discovery, as well as support the development of diagnostic solutions.
Where is Essential Bio headquartered?
Essential Bio is headquartered in Cambridge, United States.
When was Essential Bio founded?
Essential Bio was founded in 2019.
What industry does Essential Bio operate in?
Essential Bio operates in Biotech, Genomics, Drug Discovery, Reagents, Diagnostics, Life Sciences.
What is Essential Bio's current status?
Essential Bio's current operating status is: Inactive.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Leading AI agency in Guwahati specializing in biological intelligence, generative AI, and regulatory systems for Asia's underrepresented populations.
Spearmint Resources Inc. is a Canadian mineral exploration company focused on lithium, gold, and antimony projects.
Eccoscience is a startup focused on developing AI-powered solutions for scientific research and discovery.
Feef is a voice-native AI agent that designs personalized fitness, nutrition, supplement, and recovery protocols, integrating them directly into your calendar.
Longevity and metabolic health platform offering personalized insights and interventions.
AI-powered platform for personalized health and longevity.
An entrant is a company tagged Biotech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 1 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.